Bavarian Nordic A/S announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succeeding Paul Chaplin, whose departure was announced earlier this year. Stenvall is a global healthcare executive with over 20 years of leadership experience at Sanofi, AstraZeneca, and Pfizer, most recently serving as Senior Vice President and Head of Global Franchise for diabetes and cardiovascular diseases at Sanofi, where she oversaw global portfolio strategy and long-term planning for a 10 billion euro franchise. She has led organizations of more than 3,000 people and held more than 3 billion euros in profit-and-loss responsibility. Anne Louise Eberhard, Chair of the Board of Directors, said the Board appointed Stenvall following a comprehensive search and expressed appreciation to Paul Chaplin, under whose leadership the company evolved from a research-focused organization into a global vaccines company. Effective October 15, 2026, the Executive Management of Bavarian Nordic will consist of Tarja Stenvall as President and Chief Executive Officer, Henrik Juuel as EVP and Chief Financial Officer, Jean-Christophe May as EVP and Chief Commercial Officer, and Russell Thirsk as EVP and Chief Operating Officer.
Bavarian Nordic A/SBavarian Nordic appoints new CEO Tarja Stenvall; leadership change with no stated financial or operational effect
AstraZeneca PLC
Pfizer Inc
Sanofi SA